Second Primary Malignancies in Patients with Neuroendocrine Tumors Abstract #1112

Introduction: Numerous studies have demonstrated an elevated incidence of second primary malignancies (SPM) in patients with neuroendocrine tumours (NET).
Aim(s): To review our institutional experience of SPM in NET patients.
Materials and methods: Individual patient notes were obtained: data regarding gender, age, date and type of diagnoses were extracted. Patients with any tumour pre-disposition syndrome were excluded. SPM were classed as previous, synchronous, or metachronous relative to NET diagnosis. A person-year methodology was used to compare the observed frequencies of SPM against expected values generated using age- and sex-specific incidence tables, with standardised incidence ratios (SIRs) and 95% confidence intervals (CI) calculated.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Ashley Clift

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi
#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis
Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Ashley Clift
Authors: Clift A, Frilling A, Braat A, Alsafi A, ...
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#1562 Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neoplasms
Introduction: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a recognised therapeutic option for a range of neoplasms.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Ashley Clift
Authors: Clift A, Pai M, Habib N, Senturk H, ...